These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 17931655)

  • 1. Fenofibrate modulates cardiac and hepatic metabolism and increases ischemic tolerance in diet-induced obese mice.
    Aasum E; Khalid AM; Gudbrandsen OA; How OJ; Berge RK; Larsen TS
    J Mol Cell Cardiol; 2008 Jan; 44(1):201-9. PubMed ID: 17931655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fenofibrate prevents orotic acid--induced hepatic steatosis in rats.
    Ferreira AV; Parreira GG; Porto LC; Mario EG; Delpuerto HL; Martins AS; Botion LM
    Life Sci; 2008 Apr; 82(15-16):876-83. PubMed ID: 18374364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of BM 17.0744, a PPARalpha ligand, on the metabolism of perfused hearts from control and diabetic mice.
    Aasum E; Cooper M; Severson DL; Larsen TS
    Can J Physiol Pharmacol; 2005 Feb; 83(2):183-90. PubMed ID: 15791292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of conjugated linoleic acid on liver composition and fatty acid oxidation are isomer-dependent in hamster.
    Macarulla MT; Fernández-Quintela A; Zabala A; Navarro V; Echevarría E; Churruca I; Rodríguez VM; Portillo MP
    Nutrition; 2005 Apr; 21(4):512-9. PubMed ID: 15811773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of liver fatty acid oxidation in the leptin-deficient obese mouse.
    Brix AE; Elgavish A; Nagy TR; Gower BA; Rhead WJ; Wood PA
    Mol Genet Metab; 2002 Mar; 75(3):219-26. PubMed ID: 11914033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver.
    Harano Y; Yasui K; Toyama T; Nakajima T; Mitsuyoshi H; Mimani M; Hirasawa T; Itoh Y; Okanoue T
    Liver Int; 2006 Jun; 26(5):613-20. PubMed ID: 16762007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The PPARalpha activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy.
    Brigadeau F; Gelé P; Wibaux M; Marquié C; Martin-Nizard F; Torpier G; Fruchart JC; Staels B; Duriez P; Lacroix D
    J Cardiovasc Pharmacol; 2007 Jun; 49(6):408-15. PubMed ID: 17577106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate.
    Forcheron F; Abdallah P; Basset A; del Carmine P; Haffar G; Beylot M
    Obesity (Silver Spring); 2009 Jul; 17(7):1381-9. PubMed ID: 19553925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in liver PPARalpha mRNA expression in response to two levels of high-safflower-oil diets correlate with changes in adiposity and serum leptin in rats and mice.
    Hsu SC; Huang CJ
    J Nutr Biochem; 2007 Feb; 18(2):86-96. PubMed ID: 16713235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotype-based treatment of dietary obesity: differential effects of fenofibrate in obesity-prone and obesity-resistant rats.
    Ji H; Outterbridge LV; Friedman MI
    Metabolism; 2005 Apr; 54(4):421-9. PubMed ID: 15798946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice.
    Berthou L; Duverger N; Emmanuel F; Langouët S; Auwerx J; Guillouzo A; Fruchart JC; Rubin E; Denèfle P; Staels B; Branellec D
    J Clin Invest; 1996 Jun; 97(11):2408-16. PubMed ID: 8647932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease.
    Hong XZ; Li LD; Wu LM
    Clin Exp Pharmacol Physiol; 2007; 34(1-2):27-35. PubMed ID: 17201732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microarray analysis of gene expression changes in mouse liver induced by peroxisome proliferator- activated receptor alpha agonists.
    Yamazaki K; Kuromitsu J; Tanaka I
    Biochem Biophys Res Commun; 2002 Jan; 290(3):1114-22. PubMed ID: 11798191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic activation of peroxisome proliferator-activated receptor-alpha with fenofibrate prevents alterations in cardiac metabolic phenotype without changing the onset of decompensation in pacing-induced heart failure.
    Labinskyy V; Bellomo M; Chandler MP; Young ME; Lionetti V; Qanud K; Bigazzi F; Sampietro T; Stanley WC; Recchia FA
    J Pharmacol Exp Ther; 2007 Apr; 321(1):165-71. PubMed ID: 17215446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the actions of peroxisome proliferator-activated receptor alpha on obesity by estrogen.
    Jeong S; Yoon M
    Obesity (Silver Spring); 2007 Jun; 15(6):1430-40. PubMed ID: 17557980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Green tea (-)-epigallocatechin-3-gallate reduces body weight with regulation of multiple genes expression in adipose tissue of diet-induced obese mice.
    Lee MS; Kim CT; Kim Y
    Ann Nutr Metab; 2009; 54(2):151-7. PubMed ID: 19390166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisomal-proliferator-activated receptor alpha activates transcription of the rat hepatic malonyl-CoA decarboxylase gene: a key regulation of malonyl-CoA level.
    Lee GY; Kim NH; Zhao ZS; Cha BS; Kim YS
    Biochem J; 2004 Mar; 378(Pt 3):983-90. PubMed ID: 14641110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of dyslipidemia, insulin sensitivity, and energy balance by a peroxisome proliferator-activated receptor alpha agonist.
    Chen X; Matthews J; Zhou L; Pelton P; Liang Y; Xu J; Yang M; Cryan E; Rybczynski P; Demarest K
    Metabolism; 2008 Nov; 57(11):1516-25. PubMed ID: 18940388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of obesity and lipid disorders by herbal extracts from Morus alba, Melissa officinalis, and Artemisia capillaris in high-fat diet-induced obese mice.
    Lee J; Chae K; Ha J; Park BY; Lee HS; Jeong S; Kim MY; Yoon M
    J Ethnopharmacol; 2008 Jan; 115(2):263-70. PubMed ID: 18023310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice.
    Yu XX; Murray SF; Pandey SK; Booten SL; Bao D; Song XZ; Kelly S; Chen S; McKay R; Monia BP; Bhanot S
    Hepatology; 2005 Aug; 42(2):362-71. PubMed ID: 16001399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.